A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if imexon in combination with gemcitabine could
improve overall survival as compared to gemcitabine alone in subjects with pancreatic cancer
that has spread to other organs such as the liver or lungs. The study will also look at the
safety of the combination as compared to gemcitabine alone. Participants in the study will be
randomly assigned to either treatment and neither the participant or their doctors will know
which treatment they will be receiving.